SCHEMBL340652

SCHEMBL340652

O=c1[nH]c2ncccc2o1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.61
HSD17B10 Q99714 1/20 0.61
OGT O15294 1/20 0.48
GRM5 P41594 3/20 0.44
AURKA O14965 1/20 0.43
PARP1 P09874 1/20 0.43
PDE3B Q13370 3/20 0.41
PDE3A Q14432 3/20 0.41
DAO P14920 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
SYK P43405 3/20 0.40
FEN1 P39748 1/20 0.39
MCL1 Q07820 1/20 0.37
ADORA2A P29274 1/20 0.37
ADORA1 P30542 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29578046 1.00 HTT (0.61) HTTHSD17B10OGTGRM5AURKA
Hydrochloric Acid SCHEMBL30693613 0.98 HTT (0.59) HTTHSD17B10OGTGRM5AURKA
SCHEMBL9588982 0.98 HTT (0.59) HTTHSD17B10OGTGRM5AURKA
SCHEMBL9588973 0.98 HTT (0.59) HTTHSD17B10OGTGRM5AURKA
SCHEMBL19897476 0.77 PARP1 (0.46) HTTHSD17B10OGTGRM5AURKA
SCHEMBL1522777 0.77 PARP1 (0.53) HTTHSD17B10AURKAPARP1ALDH1A1
SCHEMBL29422383 0.76 HSD17B10 (1.00) HTTHSD17B10AURKAPARP1KDM4E
SCHEMBL778314 0.76 HSD17B10 (1.00) HTTHSD17B10AURKAPARP1KDM4E
SCHEMBL341634 0.68 NOS1 (0.37) HTTHSD17B10OGTAURKAPARP1
SCHEMBL14714612 0.68 PDE3B (0.37) OGTGRM5PDE3BPDE3AMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 392 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3768675-B1 NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORP (KR) 2026-04-01 EP claimed
EP-4678634-A1 ANDROGEN RECEPTOR MODULATORS AND USES THEREOF Haihe Biopharma Co., Ltd. (CN) 2026-01-14 EP claimed
CN-119447462-A Electrolyte, battery and electric equipment 厦门海辰储能科技股份有限公司 2025-02-14 CN claimed
WO-2024183793-A1 ANDROGEN RECEPTOR MODULATORS AND USES THEREOF 上海海和药物研究开发股份有限公司 2024-09-12 WO claimed
CN-118223047-A Method for synthesizing N-Mannich alkali compound by taking methanol as carbon source under electric assistance 天津科技大学 2024-06-21 CN claimed
US-11780830-B2 Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same YUHAN CORPORATION (KR) 2023-10-10 US claimed
CN-114094189-B Lithium secondary battery electrolyte and lithium secondary battery 广州天赐高新材料股份有限公司 2023-07-28 CN claimed
US-11492335-B2 Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same YUHAN CORPORATION (KR) 2022-11-08 US claimed
CN-110950888-B Preparation method of chlorooxanone with Vilsmeier reagent 山东省科学院菏泽分院 2022-05-20 CN claimed
CN-114094189-A Lithium secondary battery electrolyte and lithium secondary battery 广州天赐高新材料股份有限公司 2022-02-25 CN claimed
CN-110950888-A Preparation method of chlorooxanone with Vilsmeier reagent 山东省科学院菏泽分院 2020-04-03 CN claimed
US-10562865-B2 Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same YUHAN CORPORATION (KR) 2020-02-18 US claimed
US-20190322655-A1 NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORPORATION (KR) 2019-10-24 US claimed
US-20190308944-A1 NOVEL ARYL OR HETEROARYL TRIAZOLONE DERIVATIVES OR SALTS THEREOF, OR PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORPORATION (KR) 2019-10-10 US claimed
WO-2019180646-A1 NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORPORATION (KR) 2019-09-26 WO claimed
WO-2019180644-A1 NOVEL ARYL OR HETEROARYL TRIAZOLONE DERIVATIVES OR SALTS THEREOF, OR PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORPORATION (KR) 2019-09-26 WO claimed
EP-0357675-A4 PYRIDOOXAZINONE-PYRIDONE COMPOUNDS, CARDIOTONIC COMPOSITIONS INCLUDING THE SAME, AND THEIR USES 1992-01-15 EP claimed
EP-0357675-A1 PYRIDOOXAZINONE-PYRIDONE COMPOUNDS, CARDIOTONIC COMPOSITIONS INCLUDING THE SAME, AND THEIR USES RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) 1990-03-14 EP claimed
WO-1988008706-A1 PYRIDOOXAZINONE-PYRIDAZINONE AND PYRAZOLONE COMPOUNDS, CARDIOTONIC COMPOSITIONS INCLUDING THE SAME, AND THEIR USE RORER INTERNATIONAL (OVERSEAS) INC. (US) 1988-11-17 WO claimed
WO-1988008705-A1 PYRIDOOXAZINONE-PYRIDONE COMPOUNDS, CARDIOTONIC COMPOSITIONS INCLUDING THE SAME, AND THEIR USES RORER INTERNATIONAL (OVERSEAS) INC. (US) 1988-11-17 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190322655-A1 NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME SLC10A1, VAPB, VAT1 HTT 2516/4885HSD17B10 133/4885OGT 2086/4885
US-11492335-B2 Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same CYP7A1, NAT1, NCOA1 HTT 949/4885HSD17B10 47/4885OGT 1610/4885
US-10562865-B2 Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same CYP7A1, NAT1, NCOA1 HTT 949/4885HSD17B10 47/4885OGT 1610/4885
US-20190308944-A1 NOVEL ARYL OR HETEROARYL TRIAZOLONE DERIVATIVES OR SALTS THEREOF, OR PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME CYP7A1, VAPB, SLC10A1 HTT 1397/4885HSD17B10 56/4885OGT 1457/4885
US-11780830-B2 Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same SLC10A1, VAT1, LIPC HTT 2230/4885HSD17B10 146/4885OGT 1883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.